跳至主要内容
临床试验/JPRN-UMIN000018453
JPRN-UMIN000018453已完成未知

Relationship between viral clearance and prevention of carcinogenesis in patients with chronic hepatitis genotype2 treated with sofosuvubir plus ribavirin combination therapy - Efficacy of sofosuvubir plus ribavirin combination therapy for patients with chronic hepatitis genotype 2

ippon Medical School Chiba Hokusoh Hospital0 个研究点目标入组 300 人开始时间: 2015年7月29日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
300

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18years-old 至 80years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1. History of allergy to sofosubuvir, Ribavirin, and other nucleotide analog. 2. severe renal disorder or chronic renal failure on hemodialysis 3. medication with carbamazepine, phenytoin, rifampicin, St. John's wort 4. pregnant woman or lactating mother 5. poorly controlled heart disease 6. hemoglobinopathy 7. severe depression 8. autoimmune hepatitis 9. Hepatocellular carcinoma, or other malignant tumor 10. severe liver disorder (T-Bil>3.0mg/dL, and/or PT%<70%, and/or Alb<3.4g/dL) 11. Judged by investigator not to be appropriate for inclusion in this study

研究者

发起方
ippon Medical School Chiba Hokusoh Hospital

相似试验